1	Emergence of the SARS-CoV-2 B.1.1.7 lineage and its characteristics at an outpatient
2	testing site in Berlin, Germany, January-March 2021
3	
4	Welmoed van Loon ¹ , Heike Rössig ² , Susen Burock ³ , Jörg Hofmann ⁴ , Julian Bernhardt ¹ ,
5	Elizabeth Linzbach ¹ , Domenika Pettenkofer ¹ , Christian Schönfeld ¹ , Maximilian Gertler ¹ ,
6	Joachim Seybold ² , Tobias Kurth ⁵ , Frank P. Mockenhaupt ¹
7	
8	1 Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin
9	Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,
10	Berlin, Germany
11	2 Medical Directorate, Charité - Universitätsmedizin Berlin, corporate member of Freie
12	Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
13	3 Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, corporate
14	member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
15	4 Labor Berlin - Charité Vivantes GmbH, Berlin, Germany
16	5 Institute of Public Health, Charité-Universitätsmedizin Berlin, corporate member of Freie
17	Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
18	
19	Corresponding author: Welmoed van Loon, <u>welmoed.van-loon@charite.de</u>
20	
21	Abstract
22	Within five weeks in early 2021, B.1.1.7 became the dominant SARS-CoV-2 lineage at an
23	outpatient testing site in Berlin. Characteristics including Ct-values of 193 and 125 recently ill
24	outpatients with B.1.1.7 and wildtype virus, respectively, were similar, except for more
25	commonly reported sore throat and travel, and less frequently stated loss of smell and taste in
26	the former.

27 The SARS-CoV-2 B.1.1.7 lineage (variant of concern [VOC] 202012/01, or 20I/501Y.V1)

28 likely emerged during autumn 2020 in the United Kingdom and quickly became the dominant

strain (1). It carries multiple mutations and deletions, including 501Y and deletion

 $\Delta H69/\Delta V70$ (del69–70) in the spike protein. The B.1.1.7 variant is considered to exhibit

31 increased transmissibility compared to non-VOC lineages (1), hereafter referred to as

32 wildtype virus, whereas increased fatality is ambiguous (2,3).

At the outpatient SARS-CoV-2 testing site of Charité - Universitätsmedizin Berlin, the first patient infected with the B.1.1.7 variant was identified on January 18, 2021. Herein, we describe lineage prevalence over time as well as demographic and clinical characteristics in outpatients with the B.1.1.7 variant and those with the wildtype virus presenting until end of March. Ethical approval for the analysis was obtained from Charité's institutional review board (EA4/083/20).

39

40 The study

41 Details of the testing site have been described (4). Upon presentation, physicians interviewed patients on demographics, medical history, and symptoms. If indicated, an combined oro-42 nasopharyngeal swab was collected. SARS-CoV-2 infection was assessed applying a cobas® 43 6800/8800 analyzer (Roche Diagnostics, Mannheim, Germany), targeting both ORF1ab and E 44 Gene (5). All positive samples were typed for the N501Y and del69–70 polymorphisms by 45 melting curve analysis. Variants including both polymorphisms were considered B.1.1.7. 46 Between January 18 and March 29, 2021, 349 SARS-CoV-2 positive patients 47 presented. In this period, the proportion of the B.1.1.7 variant increased from 2% to >90% 48 (Figure 1). In total, 35.8% (125/349) of the samples belonged to the wildtype lineage, 57.0% 49 (199/349) were the B.1.1.7 variant, and 7.2% (25/349) other non-wildtype variants (non-50 VOCs). 51 Six patients previously had received ≥ 1 SARS-CoV-2 vaccination (five, first dose 52 AZD1222 [Oxford-AstraZeneca] 4-24 days before; one, second BNT162b2 53 54 [Pfizer/BioNTech] dose 66 days before); all were infected with B.1.1.7 and were excluded

from analysis as were patients carrying lineages other than wildtype or B.1.1.7. Half of the

- patients were female (49%); mean age was 36 ± 15 years. Almost all reported symptoms
- 57 (97%). Median symptom duration until testing was 3 days (IQR, 2, 4). Leading complaints
- were fatigue (72%), headache (69%), and muscle ache (60%). Fifteen percent reported travel

outside of Berlin in the last fourteen days, and half (49%) had had contact with a confirmed
SARS-CoV-2 case (Table 1).

Most assessed characteristics did not substantially differ between patients carrying the 61 SARS-CoV-2 wildtype or the B.1.1.7 lineage, including age, sex, leading complaints, 62 symptom duration, contacts to a confirmed case, and time passed since such contacts (Table 63 1). However, B.1.1.7 patients had travelled more frequently than those infected with the 64 wildtype strain (19% vs. 10%). As for symptoms, patients with B.1.1.7 more often reported 65 sore throat than those with the wildtype lineage (54% vs. 42%) but less often loss of 66 67 smell/taste (24% vs. 38%) (Table 1). We observed no difference in cycle threshold (Ct)-values for the E Gene target 68 69 between B.1.1.7 and wildtype samples (medians, 20.2 vs. 20.1) (Table 1). In patients reporting a symptom duration of \geq 7 days, Ct-values appeared to be lower for the B.1.1.7 lineage 70 71 (median, 26.2; wildtype, 30.1; Mann-Whitney-U-test, P=0.7) (Table 1, Figure 2). Lastly, we explored which combination of variables in our dataset best predicted the 72 73 B.1.1.7 variant in a logistic regression applying a backward stepwise selection based on the Akaike information criterion. This identified the best set of predictors as absent loss of 74 75 smell/taste (P=0.01), longer symptom duration (P=0.02), sore throat (P=0.05), lower Ct-

value (P=0.07), travel in the last 14 days (P=0.08), lower age (P=0.09), and absent

rhinorrhea (P=0.12). We then used bootstrap technique to repeat the variable selection in

1,000 replicated datasets and evaluated how often these variables were selected with the

backward selection. This resulted in loss of smell/taste, 89%; symptom duration, 78%; travel,

80 73%; sore throat, 68%; Ct-value, 66%; age, 56%; rhinorrhea, 51%. Absent loss of smell/taste,

81 longer symptom duration, and travel were selected most often, indicating their importance in

82 B.1.1.7 variant prediction. All analyses were done in R version 3.6.3.

83

84 Discussion

The first B.1.1.7 case in Germany was notified in late December 2020 (6). At our testing site,

the B.1.1.7 lineage was first observed three weeks later and replaced the wildtype virus as the

87 dominant strain within five weeks only. The rapid emergence and dominance of this lineage

88 likely results from its increased transmissibility (1), which is potentially caused by spike

protein polymorphisms including 501Y conferring enhanced mucosal binding (7); 681H, near

a region important for transmission (8); deletion 69-70, linked to immune escape (9). Viral

91 replication *in vitro* does not differ from pre-existing strains (10).

The B.1.1.7 variant reportedly is associated with increased mortality (2), although this 92 has been questioned (3). In our young outpatient study population, we did not observe major, 93 lineage-dependent differences in leading symptoms. Nevertheless, loss of smell/taste, among 94 the most specific COVID-19 symptoms (4), was less common in patients infected with 95 B.1.1.7., whereas, sore throat was more frequently reported than in wildtype virus patients. 96 Similarly, a UK survey revealed less loss of smell/taste in B.1.1.7 patients but more sore 97 throat, cough, fatigue, myalgia, and fever (11). In contrast, no associations between SARS-98 CoV-2 B.1.1.7 and self-reported symptoms, disease duration, or hospital admissions were 99 100 seen in another UK study (12). The most important factors for B.1.1.7 infection prediction in our study appeared to be loss of smell/taste and longer symptom duration, in addition to 101 102 recent travel.

As for Ct-values, one study observed similar figures in patients infected with B.1.1.7 103 104 and wildtype lineages; however, a longer duration of infection with the B.1.1.7 variant was suggestive by repeated sampling over time (13). Likewise, longer persistence has been 105 106 observed for B.1.1.7 (14), but also lower Ct-values (higher viral load) compared to wildtype samples. Lower Ct-values were also seen in other studies on population (15) and inpatient 107 108 levels (3). In our cross-sectional assessment of recently ill outpatients, we did not observe 109 such differences. Still, increased transmissibility may result from the variant's prolonged excretion (13,14). Test timing appears crucial for the interpretation of Ct-values. Outpatients 110 are commonly tested earlier in the course of infection than inpatients. The combination of 111 prolonged viral shedding with different test timing might explain increased viral load in 112 B.1.1.7 samples in inpatients, but not in recently ill outpatients. In support of that, in our 113 outpatients with \geq 7 days symptom duration, Ct-values in B.1.1.7 samples were suggestively 114 reduced. However, the comparison groups were small. Our data enable to detect a maximum 115 effect size on overall Ct-values, which corresponds to B.1.1.7 Ct-values being 1.5 units below 116 117 wildtype, or 1.0 above.

The main limitation in our study are limited subgroup sizes, which reduced the likelihood to detect differences between rare characteristics. Others are the one-time assessment, subjective symptom duration, and the variable manifestation of SARS-CoV-2 infection (4). Strengths include standardized procedures conducted by trained medical staff and the prospective nature of the study evaluating patient groups during the same time period, reducing the likelihood of confounding due to temporal effects.

- 124 SARS-CoV-2 VOC B.1.1.7 is now the dominant lineage in Berlin. On the outpatient
- level, there appears to be no major difference in clinical manifestation.
- 126

127 Acknowledgments

- 128 We thank the Corona Untersuchungsstelle (CUS) staff at the Charité Universitaetsmedizin
- 129 Berlin for their dedication and hard work during the COVID-19 pandemic.
- 130

131 References

101	Iterer ences	
132	1.	Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Hopkins S, et al.
133		Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from
134		linking epidemiological and genetic data. MedRxiv [Preprint]. 2021 [cited 2021
135		Apr 1]. Available from:
136		https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2.
137	2.	Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ,
138		Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases
139		of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 Mar 15;1–5. doi:
140		10.1038/s41586-021-03426-1.
141	3.	Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic
142		characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage
143		in London, UK: a whole-genome sequencing and hospital-based cohort study.
144		Lancet Infect Dis. 2021 Apr 12;0(0). doi: 10.1016/S1473-3099(21)00170-5.
145	4.	Maechler F, Gertler M, Hermes J, van Loon W, Schwab F, Piening B, et al.
146		Epidemiological and clinical characteristics of SARS-CoV-2 infections at a
147		testing site in Berlin, Germany, March and April 2020-a cross-sectional study.
148		Clin Microbiol Infect. 2020 Dec;26(12):1685.e7-1685.e12. doi:
149		10.1016/j.cmi.2020.08.017.
150	5.	Poljak M, Korva M, Gašper NK, Komloš KF, Sagadin M, Uršič T, et al. Clinical
151		evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch
152		during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020
153		May 26;58(6):e00599-20. doi: 10.1128/JCM.00599-20.
154	6.	Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) Daily Situation
155		Report of the Robert Koch Institute. 26/12/2020. 2020. Available from:
156		https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberi
157		chte/Dez_2020/2020-12-26-en.pdf?blob=publicationFile
158	7.	Chan KK, Tan TJC, Narayanan KK, Procko E. An engineered decoy receptor for
159		SARS-CoV-2 broadly binds protein S sequence variants. Sci Adv. 2021 Feb
160		17;7(8):eabf1738. doi: 10.1126/sciadv.abf1738.
161	8.	Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The
162		furin cleavage site of SARS-CoV-2 spike protein is a key determinant for
163		transmission due to enhanced replication in airway cells. BioRxiv [Preprint];

164		2020 [cited 2021 Apr 14]. Available from:
165		https://doi.org/10.1101/2020.09.30.318311.
166	9.	Kemp SA, Collier DA, Datir R, Ferreira IATM, Gayed S, Jahun A, et al.
167		Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. Nature.
168		2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y.
169	10.	Brown JC, Goldhill DH, Zhou J, Peacock TP, Frise R, Goonawardane N, et al.
170		Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is
171		not accounted for by a replicative advantage in primary airway cells or antibody
172		escape. BioRxiv [Preprint]. 2021 [cited 2021 Apr 3]; Available from:
173		https://doi.org/10.1101/2021.02.24.432576.
174	11.	Office for National Statistics. Coronavirus (COVID-19) Infection Survey:
175		characteristics of people testing positive for COVID-19 in England. 2021.
176		Available from:
177		https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/co
178		nditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengl
179		and/characteristicsofpeopletestingpositiveforcovid19inengland27january2021
180	12.	Graham MS, Sudre CH, May AM, Antonelli M, Murray B, Varsavsky T, et al.
181		Changes in symptomatology, re-infection and transmissibility associated with
182		SARS-CoV-2 variant B.1.1.7: an ecological study The COVID-19 Genomics
183		UK (COG-UK) consortium. MedRxiv [Preprint]. 2021 [cited 2021 Apr 1];
184		Available from:
185		https://www.medrxiv.org/content/10.1101/2021.01.28.21250680v2.
186	13.	Kissler SM, Fauver JR, Mack C, Tai CG, Watkins AE, Samant RM, et al.
187		Densely sampled viral trajectories suggest longer duration of acute infection
188		with B.1.1.7 1 variant relative to non-B.1.1.7 SARS-CoV-2 2 3. MedRxiv
189		[Preprint]. 2021 [cited 2021 Mar 30]; Available from:
190		https://doi.org/10.1101/2021.02.16.21251535.
191	14.	Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al.
192		Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by
193		longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J
194		Infect Dis. 2021 Mar 5;105:753-755. doi: 10.1016/j.ijid.2021.03.005.
195	15.	Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant
196		SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in

- 197 samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis. 2021 Feb
- 198 13:jiab082. doi: 10.1093/infdis/jiab082.

200 Table 1. Characteristics of SARS-CoV-2 positive outpatients attending the Charité


201 testing site, separated by wildtype and B.1.1.7 lineages

	Wildtype lineage	B.1.1.7 variant	OR [95%CI], difference in mean
	N=125 (%, mean [SD], or median [25 th , 75 th quantile])	N=193 (%, mean [SD], or median [25 th , 75 th quantile])	[95%CI], or difference in median [95%CI] [*]
Female	44.8%	51.0%	1.3 (0.8, 2.0)
Age, years	36.6 (13.8)	34.8 (15.9)	1.8 (-1.5, 5.1)
Any symptoms	97.6%	96.4%	0.7 (0.2, 2.6)
Self-reported fever in the last 48 hours	38.4%	42.5%	1.2 (0.8, 1.9)
Temperature in case of fever (°C, by patient statement)	38.3 (0.6)	38.2 (0.7)	0.1 (-0.2, 0.4)
Short of breath	9.6%	13.5%	1.5 (0.7, 3.0)
Fatigue	73.6%	71.5%	0.9 (0.5, 1.5)
Pain on the chest	2.4%	1.0%	0.4 (0.1, 2.6)
Diarrhea	15.2%	12.4%	0.8 (0.4, 1.5)
Loss of smell/taste	37.6%	23.8%	0.5 (0.3, 0.9)
Muscle ache	60.0%	60.1%	1.0 (0.6, 1.6)
Sore throat	41.6%	53.9%	1.6 (1.0, 2.6)
Cough	48.8%	50.8%	1.1 (0.7, 1.7)
Headache	68.8%	68.9%	1.0 (0.6, 1.6)
Chills	35.2%	34.7%	1.0 (0.6, 1.6)
Rhinorrhea	60.8%	52.8%	0.7 (0.5, 1.1)
Symptom duration upon test (days)	3.0 (2.0, 4.8)	3.0 (2.0, 4.0)	0.0 (-1.0, 0.0)
Contact to a confirmed SARS-CoV-2 case	48.0%	50.3%	1.1 (0.7, 1.7)
Time between contact to a confirmed SARS-CoV-2 case and test (days)	4.0 (1.2, 7.0)	4.0 (1.0, 6.0)	0.0 (-1.5, 3.0)
Traveled outside the	9.6%	18.7%	2.2 (1.1, 4.3)

Wildtype lineage	B.1.1.7 variant	OR [95%CI], difference in mean
N=125	N=193	[95%CI], or difference in
(%, mean [SD], or median [25 th , 75 th quantile])	(%, mean [SD], or median [25 th , 75 th quantile])	median [95%CI]*
20.2 (17.4, 24.1)	20.1 (17.1, 22.8)	0.1 (-0.9, 1.6)
N=113; 19.9 (17.4, 23.5)	N =171; 19.5 (16.6, 22.6)	0.4 (-1.0, 1.7)
N=6; 30.1 (26.1, 31.3)	N=11; 26.2 (21.4, 31.2)	3.9 (-5.6, 10.0)
	N=125 (%, mean [SD], or median [25 th , 75 th quantile]) 20.2 (17.4, 24.1) N=113; 19.9 (17.4, 23.5) N=6;	N=125N=193(%, mean [SD], or median [25 th , 75 th quantile])(%, mean [SD], or median [25 th , 75 th quantile]) $20.2 (17.4, 24.1)$ $20.1 (17.1, 22.8)$ N=113; 19.9 (17.4, 23.5)N =171; 19.5 (16.6, 22.6)N=6;N=11;

* The 95% confidence interval for the difference in medians was computed by a percentile

203 bootstrap with 1,000 replications.



205

Figure 1. Proportion of SARS-CoV-2 lineages at the Charité testing site, 2021. The

207 numbers on top of the bars indicate the total number of positive SARS-CoV-2-tests assessed.

208 Six (partially) vaccinated outpatients are included for completeness. Note that calendar week

209 13 only includes one day (March 29).






Figure 2. Comparison of median Ct-values in SARS-CoV-2 wildtype and B.1.1.7 lineage,

by symptom duration. The boxplots indicate medians, 25th and 75th percentiles (i.e., Q1 and

214 Q3). The upper whiskers reach the largest value with a maximum Q3 + 1.5 * interquartile

range (IQR). The lower whiskers reach the smallest value with a minimum Q1 - 1.5 * IQR.

216 The numbers on top of the boxplots indicate the total number of observations included in the

217 comparison.